Naïve/Effector CD4 T cell ratio as a useful predictive marker of immune reconstitution in late presenter HIV patients: A multicenter study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
06
2019
accepted:
03
11
2019
entrez:
24
12
2019
pubmed:
24
12
2019
medline:
24
3
2020
Statut:
epublish
Résumé
A significant proportion of HIV-infected patients experiencing a late diagnosis highlights the need to define immunological protocols able to help the clinicians in identifying patients at higher risk for immunological failure. The aim of the study was to evaluate the feasibility of easy cytometric tests in defining the effect of antiretroviral treatment (cART) on immunological homeostasis and in identifying predictive markers of early immune recovery. Chronic HIV infected patients (n = 202) were enrolled in a prospective multicentric study, and their immunological profile was studied before (w0) and after 24 weeks (w24) of antiretroviral treatment (cART) using a standardized flow cytometric panel. Based on CD4 T cell count before treatment, patients were divided in late (LP: CD4 <350/mmc), intermediate (IP: 350/mmc<CD4<500/mmc) and early (EP: CD4 >500/mmc) presenters. In all groups, cART introduction increased CD4 and CD4/CD8 T cell ratio, naïve T cell (CD4 and CD8) and CD127-expressing CD4 T cells. In parallel, cART significantly reduced effector memory T cells (CD4 and CD8) and T cell activation (CD38+CD8 and CD95+CD4 T cells). Moreover, the frequency of Naïve and Effector CD4 T cells before treatment correlated with several immune parameters key associated with the pathogenesis of HIV, thus mirroring the health of immune system. Interestingly, we identified the Naïve/Effector CD4 T cell ratio (N/EM) at w0 as a marker able to predict early immune recovery. Specifically, in LP, N/EM ratio was significantly higher in immunological responder patients (CD4>500/mmc at w24) when compared to immunological non responder (CD4 T cells <500/mmc at w24). Finally, a multivariate analysis indicates that after 24w patients with N/EM ratio higher than 1.86 at w0 recovered 96 CD4 T cells more than those with N/EM ratio lower than 0.46. Altogether, our data define an easy protocol able to define reliable immunological markers useful for the characterization of immune profile in viremic HIV patients and identify the naïve/effector CD4 T cell ratio as a new tool able to predict an early immune reconstitution potential.
Identifiants
pubmed: 31869342
doi: 10.1371/journal.pone.0225415
pii: PONE-D-19-17484
pmc: PMC6927630
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0225415Déclaration de conflit d'intérêts
The support of Becton Dickinson does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Adv Immunol. 2013;119:51-83
pubmed: 23886064
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Clin Infect Dis. 2007 Feb 1;44(3):441-6
pubmed: 17205456
PLoS Pathog. 2014 May 15;10(5):e1004078
pubmed: 24831517
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):72-7
pubmed: 17621240
J Antimicrob Chemother. 2012 Jul;67(7):1802-4
pubmed: 22461310
AIDS. 2016 Aug 24;30(13):2033-42
pubmed: 27191978
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):338-344
pubmed: 28418988
Clin Immunol. 2018 Oct;195:127-138
pubmed: 29883708
J Infect Dis. 2014 Aug 15;210(4):619-29
pubmed: 24585897
AIDS. 2008 Apr 23;22(7):841-8
pubmed: 18427202
AIDS. 2006 Oct 24;20(16):2033-41
pubmed: 17053349
AIDS. 2013 Mar 13;27(5):769-79
pubmed: 23719349
J Clin Immunol. 2005 Mar;25(2):106-15
pubmed: 15821887
Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):415-24
pubmed: 22697073
Curr HIV Res. 2016;14(6):491-496
pubmed: 27074946
Semin Immunol. 2012 Jun;24(3):231-40
pubmed: 22421574
Clin Infect Dis. 2005 Aug 1;41(3):361-72
pubmed: 16007534
Curr HIV/AIDS Rep. 2015 Mar;12(1):33-40
pubmed: 25578055
Lancet HIV. 2015 Mar;2(3):e98-106
pubmed: 26424550
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8732-7
pubmed: 11447288
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28559274
J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):483-92
pubmed: 26627102
J Infect Dis. 2011 Oct 15;204(8):1217-26
pubmed: 21917895
JCI Insight. 2017 Oct 19;2(20):
pubmed: 29046481
Nat Immunol. 2000 Nov;1(5):426-32
pubmed: 11062503
Chin Med J (Engl). 2016 20th Nov;129(22):2683-2690
pubmed: 27824000
N Engl J Med. 2017 Jul 20;377(3):283-284
pubmed: 28723319
AIDS. 2010 Oct 23;24(16):2590-3
pubmed: 20935556
J Acquir Immune Defic Syndr. 2010 May 1;54(1):59-62
pubmed: 20182359
Blood. 2011 May 26;117(21):5582-90
pubmed: 21403129
Curr Opin HIV AIDS. 2008 May;3(3):342-8
pubmed: 19372988
Front Microbiol. 2018 Jul 02;9:1451
pubmed: 30034377